Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJA
This is a prospective, multicenter, single-group clinical study of Apatinib Plus Irinotecan as second-line treatment in locally advanced or metastatic gastric or gastroesophageal junctional adenocarcinoma.
Metastatic Gastric Adenocarcinoma
DRUG: Apatinib|DRUG: Irinotecan
Progression Free Survival [PFS], Progression Free Survival, 5-6 months
Overall Survival [OS], Overall Survival, 12-15 months|Objective Response Rate [ORR], Objective Response Rate, 12-15 months|Disease Control Rate [DCR], Disease Control Rate, 12-15 months
Incidence and Degree of Treatment-Emergent Adverse Events [Safety and Tolerability], Incidence and Degree of Treatment-Emergent Adverse Events, 12-15 months|Performance Status [WHO-ECOG], Performance Status, 12-15 months|Quality of Life [WHO-QOL], Quality of Life, 12-15 months
This is a prospective, multicenter, single-group clinical study of Apatinib Plus Irinotecan as second-line treatment in locally advanced or metastatic gastric or gastroesophageal junctional adenocarcinoma. Interventions: Irinotecan: 180mg/m2, ivgtt,given on the first day; Apatinib: initial dose: 250mg,oral,once a day, after meal ( try to take the medicine at the same time each day). Repeat the therapeutic schedule every 3 weeks till progressive disease or intolerable toxicities. Primary Outcome Measure: PFS. Secondary Outcome Measures: OS, ORR, DCR.